Recent developments in the treatment of chronic hepatitis B virus infection

References

• LAU JY, WRIGHT TL: Molecular virology and pathogenesis of hepatitis B. Lancet (1994) 342:1333–1340.
   Google Scholar
• An excellent review of the mechanism of HBV replication and how hepatitis B induces liver disease.
   Google Scholar
• YOFFE B, NOONAN CA: Hepatitis B virus. New and evolving issues. Dig. Dis. Sci. (1992) 37:1–9.
   PubMed Web of Science ®Google Scholar
• HORVATH J., RAFFANTI SP: Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin. Inf Dis. (1994) 18:339-347. This review discusses how the interaction between the HIV virus and hepatitis viruses alters viral replication of each species.
   Google Scholar
• HARRISON TJ, DUSHEIKO GM: Hepatitis B virus and hepatitis delta virus. Mol. Cell. Biol. Human Dis. Series (1992) 1:203–232.
   PubMedGoogle Scholar
• ILAN Y, ASHUR Y, TUR-KASPA R, SHOUVAL D: Chronic hepatitis C virus infection with exposure to hepatitis B virus. Israeli Med. Sci. (1994) 30:259–263.
   PubMedGoogle Scholar
• IKEDA K, SAITOH S, KOIDAL I, ASASE Y, TSUBOTA A, CHAYAMA K, KUMADA H, KAWANISHI M: A multivariate analysis of risk factors for hepatocelhilar carcinogene-sis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology (1993) 18:47–53.
   PubMed Web of Science ®Google Scholar
• PETERS M, WELLEK S, DIENES HP, JUNGINGER T, MEYER J, MEYER ZUM BUSCHENDFELDE KH, GERKEN G: Epidemiology of hepatocellular carcinoma. Evaluation of viral and other risk factors in a low-endemic area for hepatitis B and C. Zeitschrift fur Gastroenterol. (1994) 32:146–151.
   Google Scholar
• A good overview of the multitude of risk factors that lead to liver cancer development.
   Google Scholar
• ULRICH PP, BHAT RA, KELLY I, BRUNETTO MR, BONINO F, VYAS GN: A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease. J. Med. Virol. (1990) 32:109–118.
   PubMed Web of Science ®Google Scholar
• The first detailed report of a hepatitis B mutant virus.
   Google Scholar
• SOKAL EM, ULLA L, OTTE JB: Hepatitis B vaccine re-sponse before and after transplantation in 55 extra-hepatic billary atresiae children. Dig. Dis. Sci. (1992) 37:1250–1252.
   PubMed Web of Science ®Google Scholar
• An analysis of the impact of chronic liver disease and immunosup-pression on the immunogenicity of hepatitis B vaccination.
   Google Scholar
• SAMUEL D, MULLER R, ALEXANDER G, FASSATI L, DUCOT B, BENAHMOU JP, BISMUTH H: Liver transplantation in European patients with the hepatitis B surface antigen. New Engl. J. Med. (1993) 329:1842–1847.
   PubMed Web of Science ®Google Scholar
• This publication is a detailed report on factors important in the prevention of liver graft reinfection with HBV after liver transplan-tation including viral serology and treatment with hepatitis B immune globulin.
   Google Scholar
• MISSALE F, BREMSJJ, TAKIFF H, POCKROS PJ, CHISARI FV:Human leukocyte antigen class I-independent path-ways may contribute to hepatitis B virus-induced liver disease after liver transplantation. Hepatology (1993) 18:491–496.
   PubMed Web of Science ®Google Scholar
• OKUDA K: New trends in hepatocellular carcinoma. Int. J. din. Lab. Res. (1993) 23:173–178.
   PubMedGoogle Scholar
• A review of recent developments in the pathogenesis and treatment of liver cancer.
   Google Scholar
• KORBA BE, MILMAN G: A cell culture assay for cornpounds which inhibit hepatitis B virus replication. Antiviral Res. (1991) 15:217–228.
   PubMed Web of Science ®Google Scholar
• This study proposes the use of a cell culture system for predicting the antiviral activity of compounds that may inhibit HBV replication.
   Google Scholar
• PERRILLO RP, SCHIFF ER, DAVIS GL, BODENHEIMER HC JR., LINDSAY K, PAYNE J, DTENSTAG JL, O'BRIEN C, TAM-BURRO C, JACOBSON IM, SAMPLINER R, FEIT D, LEFKOWITCH J, KUHNS M, MESCHIEVITZ C, SANGHVI B, ALBRECHT J, GIBAS A, HEPATITIS INTERVENTIONAL THERAPY GROUP: A randomized, controlled trial of Interferon alpha-2b alone or after prednisone with-drawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. New Engl. J. Med. (1990) 323:295–301.
   Google Scholar
• The first prospective randomized controlled trial that documented the efficacy of interferon in the treatment of HBV infection and identified subsets of patients with a higher likelihood of response.
   Google Scholar
• PERRI:ILO RP. Treatment of chronic hepatitis B with interferon: experience in western countries. Semin.Liver Ds. (1989) 9:240–241.
   PubMed Web of Science ®Google Scholar
• An excellent overview of hepatitis treatment.
   Google Scholar
• HOOFNAGLE JH, DI BISCEGLIE AM: Treatment of chronic type C hepatitis with alpha interferon. Semin. Liver Dig. (1989) 9:259–263.
   PubMed Web of Science ®Google Scholar
• PRIERS M: Mechanisms of action of interferons. Semin. Liver Ms. (1989) 9: 23 5–239.
   Google Scholar
• An explanation of the molecular and biological actions of interferon is explained in a concise fashion in this well written manuscript.
   Google Scholar
• VAN THIEL DH, ZHANG X, BADDOUR N, WRIGHT HI, FRIEDLANDER L, GAVALER JS: Hepatic mononudear cell populations and MHC antigen expression in patients with chronic hepatitis B: effect of interferon-alpha. Dig. Ds. Sci. (1994) 39:970–976.
   PubMed Web of Science ®Google Scholar
• DOUKAS A, COSSU P, PODDIGHE P, TOCCO A, DEPLANO A, GARRUCCIU G, DIANA MS: Changes of serum 2',5'-oli-goadenylate synthetase activity during interferon treat-ment of chronic hepatitis C. Liver (1993) 13:253–258.
   PubMedGoogle Scholar
• RAICELA J, WOOD JR, CZAJA AJ, O'BRIEN PC, TASWELL HF, BOWYER BA, LANGE SM, ANDERSON ML, PARENT K: Long-term versus short-term treatment with recombi-nant interferon alpha-2a in patients with chronic hepa-titis B: A prospective randomized triaL Mayo din. Proc. (1990) 65:1330–1335.
   Google Scholar
• BROOK MG, MCDONALD JA, KARAY1ANNIS P, CARUSO L, FORSTER G, HARRIS JR, THOMAS HC: Randomised con-trolled trial of interferon alpha-2a (Roferon-A) for the treatment of chronic hepatitis B (HBV) infection: Fac-tors that influence response. Gut (1989) 30:1116–1122.
   PubMed Web of Science ®Google Scholar
• MCDONALD JA, CARUSO L, KARAYIANNIS P, SCULLY LJ, HARRIS JR, FORSTER GE, THOMAS HC: Diminished re-sponsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha interferon. Hepatology (1987) 7:719–723.
   PubMed Web of Science ®Google Scholar
• LOK ASF, CHUNG HT, LIU VWS, ET AL.: Long-term follow up of chronic hepatitis B patients treated with inter-feron alpha. Gastroenterology (1992) 105:1833–1838.
   Google Scholar
• This is one of the first publications to describe the presence of interferon antibodies. This article is also important because of the long period for which the patients were followed after completing treatment and the serological changes described.
   Google Scholar
• CAPALBO M, ACTIS C, MAURIZIA R, BRUNETTO R, POLI G, BALDI M, PALMISANO L, VERME G, BONINO F: Treatment of chronic hepatitis B with p interferon given intramus-cularly: a pilot study. Ital. J. GastroenteroL (1992) 24:203–205.
   PubMedGoogle Scholar
• MARU'FANI K: Changes in hepatic function and ultras-tructures of hepatocytes during treatment with inter-feron-13 and a streptococcal preparation (0K-432) in patients with HBeAg positive chronic hepatitis. Journal of Saitama Medical School (1991) 18:279–292.
   Google Scholar
• RUIZ-MORENO M, RUA MJ, MORALEDA G, GUARDIA L, MORENO A, CARRENO V: Treatment with interferon gamma versus interferons alpha and gamma in chil-dren with chronic hepatitis B. Pediatrics (1992) 90:254–258.
   PubMed Web of Science ®Google Scholar
• CARRENO V, MORENO A, GALIANA F, BARTOLOME FJ: Alphaand gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study. J. Hepatol. (1993) 17:321–325
   Google Scholar
• OZES ON, REITER Z, KLEIN S, BLATT LM, TAYLOR MW: Acomparison of interferon corn with natural recombi-nant interferon a: antiviral, antiprolfferative and NK-inducing activity. J. Interferon Res. (1992) 12:55–59.
   PubMedGoogle Scholar
• RENAULT PF, HOOFNAGLE JH: Side effects of alpha interferon. Semin. Liver Dis. (1989) 9:267–272.
   PubMedGoogle Scholar
• This review article defines the side effect profile of the most commonly used treatment for HBV infection.
   Google Scholar
• CARRENO V, TAPIA L, RYFF JC, QUIROGA JA, CASTILLO I:Treatment of chronic hepatitis C by continuous subcu-taneous infusion of interferon-alpha. J. Med. Virol. (1992) 37:215–219.
   PubMed Web of Science ®Google Scholar
• ONJI M, KONDOH H, HORIIKE N, YAMAGUCHI S, OGAWAY, KUMON I, OHTA Y: Effect of recombinant interleukin 2 on hepatitis Be antigen positive chronic hepatitis. Gut (1987) 28: 1648-1652.
   Google Scholar
• TILG H, VOGEL W, TRATKIEWICZ J, AULITZKY WE, HEROLD M, GRUBER M, GEISSLER D, UMLAUFT F, JUD-MAIER G, SCHWULERA U, ET AL: Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects, j Hepatol. (1993) 19:259–267.
   Google Scholar
• ZENIYA M, TAKAHASHI H, SATA H, NEGISHI M, MIYAZAKIH, WATANABE F, OHKOSHI H, ANDO H, AIZAWA Y, KAMEDA H: The effects of recombinant interleukhi-2 on HBE antigen positive chronic hepatitis B. Japan. J. Med. (1991) 30:292–298.
   PubMedGoogle Scholar
• BRUCH HR, KORN A, KLEIN H, MARKUS R, MALMUS K, BAUMGARTEN R, MULLER R: Treatment of chronic hepa-titis B with interferon alpha-2b and interleukin-2. Hepatol. (1993) 17\(Suppl. 3):S52–55.
   Google Scholar
• MUTC1INICK MG, APPELMAN HD, CHUNG HT, ARAGONA E, GUPTA TP, CUMMINGS GD, WAGGONER JG, HOOFNA-GLE JH, SHAFRTTZ DA: Thymosin treatment of chronic hepatitis B: a placebo controlled pilot trial. Hepatology (1991) 14:409–415.
   PubMed Web of Science ®Google Scholar
• RASI F, MUCHNICK MG, DIVIRGELIO D, PIERIMARCHI P,
   Google Scholar
• SIN1BALDI-VALLEVONA P, COLELIA F, FAVALLI C, GARACI E: Combination low-dose lymphoblastoid interferon (L-LEN) and thymosin-t therapy in the treatment of chronic hepatitis B. Hepatology (1994) 20:299A. Abstract No. 811.
   Google Scholar
• RENOUX G: The general immunopharmacology of le-vamisole. Drugs (1980) 20:89–99.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, BROIL° L, POSTISO P, PORNARO E, RUGGE M, ALBERTI A, REALDI G: Levamisole therapy in chronic type B hepatitis: results of a double-blind ran-domized trial. Gastroenterology (1986) 91:692–696.
   PubMed Web of Science ®Google Scholar
• RUIZ-MORENO M, GARCIA R, RUA MJ, SERRANO B, MORALEDA G, FEHOO E, BARTOLOME J, ORTIZ F, CASTILLO I, CARRENO V: Levamisole and interferon in children with chronic hepatitis B. Hepatology (1993) 18:264–269.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, GIUSTINA G, BROLLO L, GUIDO M, PON-TISSO P, NOVENTA F, ALBERTI A: Therapy for chronic hepatitis B with lymphoblastoid interferon and levami-sole. Hepatology (1992) 16:1115–1119.
   PubMed Web of Science ®Google Scholar
• IJICHI K, MITAMURA, K, IDA S, MACHIDA H, SHIMADA K: In vivo antiviral effects of mismatched double-stranded RNA on duck hepatitis B virus. J. Med. Virol. (1994) 43:161–165.
   PubMed Web of Science ®Google Scholar
• BANERJEE R, PRICE PM, SUNG MW, KARPEN S, ACS G: Selective inhibition of hepatitis B virus and human immunodeficiency virus sequence-promoted gene ex-pression by cotransfected poly(I):poly(C). Virology (1990) 179:410–415.
   PubMed Web of Science ®Google Scholar
• QIN SM, CHEN LY, GUO YD: [Therapeutic effects of poly bC and prednisone withdrawal followed by poly I:C on chronic type B hepatitis - results of two double-blind randomized trials.] [Chinese]. Chung Hua Nei Ko Tsa Chih (1989) 28:403–406.
   Google Scholar
• PURCELL RH, LONDON WT, MCAULIFFE VJ, PALMER AE, KAPLAN PM, GERIN JL, WAGNER J, POPPER H, LVOVSKY E, WONG DC, LEVY 11B: Modification of chronic hepati-tis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet (1976) 2:757–761.
   PubMed Web of Science ®Google Scholar
• BRODSKY I, STRAYER DR, ICRUEGER LJ, CARTER WA: Clinical studies with Ampligen (mismatched double-stranded RNA). J. Biol. Response Mod. (1985) 4:669–675.
   PubMedGoogle Scholar
• NIU J, WANG Y, DIXON R, BOWDEN S, QIAO M, EINCK L, LOCARNINI S: The use of ampligen alone and in combi-nation with gancidovir and coutnermycin Al for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Res. (1993) 21:155–171.
   PubMedGoogle Scholar
• O'BRIEN CB, GARCIA G, HENZEL B, MARTIN M, LADEN-HEIM J, GINSBERG G, HUBBELL H, STRAYER D, CARTER W: Ampligen treatment of chronic hepatitis B. Gastroen-terology (1994) 106:A952.
   Google Scholar
• MARTIN J, BOSCH, MORALEDA G, BARTOLOME J, QUI-ROGA JA, CARRENO V: Pilot study of recombinant granu-locyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology (1993) 18:775–780.
   PubMed Web of Science ®Google Scholar
• ALPER CA, KRUSICALL MS, MARCUS-BAGLEY D, CRAVEN DE, KATZ AJ, BRINK SJ, DIENSTAG JL, AWDEH Z, YUNIS EJ: Genetic prediction of nonresponse to hepatitis B vaccine. New Engl. J. Med. (1989) 321:708–712.
   PubMed Web of Science ®Google Scholar
• This study documents influence on the immune system by genetic factors that increase or decrease response to HBV vaccine.
   Google Scholar
• YAP I, GUAN R, CHAN SH: Recombinant DNA hepatitis B vaccine containing Pre-S components of the 1113V coat protein - a preliminary study on inununogenicity. Vac-cine (1992) 10:439–442.
   PubMed Web of Science ®Google Scholar
• A novel study demonstrating that it is possible to enhance the immune response to HBV by altering the vaccine protein.
   Google Scholar
• CARMEN WF, ZANETTI P, KARAYIANNIS JA, WATERS G, MANZILLO E, TANZI AJ, ZUCKERMAN AJ, THOMAS HC: Vaccine induced escape mutant of hepatitis B virus. Lancet (1990) 336:325–329.
   PubMed Web of Science ®Google Scholar
• This publication documents that the hepatitis B virus can circumvent currently available vaccines by undergoing genetic modification.
   Google Scholar
• WATERS JA, KENNEDY M, VOET P, HAUSER P, PETRE J,
   Google Scholar
• CARMAN W, THOMAS HC: Loss of the common "A" determinant of hepatitis B surface antigen by a vacdne-induced escape mutant. J. Clin. Invest. (1992) 90:2543–2547.
   PubMed Web of Science ®Google Scholar
• ZEITZ M: [Hepatitis B vaccination in dialysis patient reversibility of defective immune response by simulta-neous administration of interleultin-2.] [German]. Zeit-schrift fur Gastroenterol. (1990) 28:179–180.
   Google Scholar
• Eno A, ISHIOKA G, GREY HM, ROSE R, FARNESS P, LAFOND R, YUAN L, CHISARI FV, FURZE J, BARTHOLOMEUZ R, CHESNUT RW: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection: L Induction of a primary cri. response In man. [In Press].
   Google Scholar
• ERLICH PH, MOUSTAFA ZA, JUSTICE JC, HARFELDT, KR, KELLEY RI., OS'TBERG L: Characterization of human :monoclonal antibodies directed against hepatitis B sur-face antigen. Hum. Antibod. Hybridomas (1992) 3:2–7.
   PubMedGoogle Scholar
• MCMAHON G, EHRLICH PH, MOUSTAFA ZA, MCCARTHY LA, DOTTAVIO D, TOLPIN MD, NADLER PI, OSTBERG L: Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology (1992) 15:757–766.
   PubMed Web of Science ®Google Scholar
• DABROWSKA-BERNSTEIN B, STASIAK A, DABROWSKI M, PAWINSKA A, CIANCIARA J, LOCH T, BABIUCH L: [Evalu-ation of the treatment of chronic active hepatitis (HBsAg+) with isoprinosine. IL Immunological studies.] [Polish]. Pol. Tyg. Lek. (1990) 45:347–351.
   PubMedGoogle Scholar
• KOWALIK-MIKOLAJEWSKA B: [Course of chronic virus hepatitis B in children and attempts at modifying its treatment] Przebieg przewleklego wirusowego za-palenia vvatroby typu B u dzkci proby modyfikacjijego leczenia. [Polish]. Pol. Tyg. Lek. (1993) 48:258–260.
   PubMedGoogle Scholar
• CIANCIARA J, LASKUS T, GABINSKA E, LOCH T: Isoprinos-ine in the treatment of chronic active hepatitis type B. Scand. J. Infect. Die. (1990) 22:645–648.
   PubMed Web of Science ®Google Scholar
• GIL J, SZMIGIELSKI S, JELJASZEWICZ J, PULVERER G: Im-munotherapy of chronic active viral hepatitis B with Propionibacterium granulosum KP-45 (a 5-year follow-up report). Hepato-Gastroenterology (1992) 39:325–329.
   PubMed Web of Science ®Google Scholar
• PEFtRI110 RP, SCHIFF ER, DAVIS GL, ETAL.: A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal, in the treatment of chronic hepatitis B. New Engl. J. Med. (1990) 323:295–301.
   Google Scholar
• PERRILLO RP, REGENSTEIN FG, PETERS MG, ET AL.: Pred-nisone withdrawal followed by recombinant alpha in-terferon in the treatment of chronic type B hepatitis: A randomized, controlled trial Ann. Intern. Med. (1988) 109:95–100.
   Google Scholar
• SAGNELLI E, MAIO G, FELACAO GM, ET AL.: Serum levels of hepatitis B surface and core antigens during immu-nosuppressive treatment of HBsAg-positive chronic ac-tive hepatitis. Lancet (1980) 2:395–397.
   Google Scholar
• SUMIYAMA K, KOBAYASHI M, MIYASHIRO E, KOIKE M: Combination therapy with transfer factor and high dose stronger neomitophagen C in chronic hepatitis B In children (HBeAg positive). Acta Paediatr. Jpn. (1991) 33:327–334.
   PubMedGoogle Scholar
• SCHMIDT U, DURR HK, BODE JC: [Therapy of acute virus hepatitis with silymarin. Report of a controlled study] Zur Therapie der akuten Virushepatitis mit Silymarin. Bericht uber eine kontrollierte Studie. [German]. Verb. Dtsch. Ges. Inn. Med. (1977) 83:563–565.
   Google Scholar
• CHEN Z: [Clinical study of 96 cases with chronic hepa-titis B treated with jiedu yanggan gao by a double-blind method.] [Chinese]. Chung Hsi I Chieh Ho Tsa Chih (1990) 10:71–74.
   Google Scholar
• KAKUMU S, YOSHIOKA K, WAKITA T, ISHIKAWA T: Effects of TJ-9 Sho-saiko-to (kamp° medicine) on interferon gamma and antibody production specific for hepatitis B virus antigen in patients with type B chronic hepatitis. Int. J. Immunopharmacol. (1991) 13:141–146.
   PubMed Web of Science ®Google Scholar
• AU TY: Effect of sho-saiko-to (xiao-chai-hu-tang) on HBeAg clearance in children with chronic hepatitis B virus infection and with sustained liver disease. Am. J. Chin. Med. (1991) 19:121–129.
   PubMed Web of Science ®Google Scholar
• SHEAD A, VICKERY K, PAJDOS A, MEDHURST R, FREIMANJ, DIXON R, COSSART Y: Effects of Phyllantbus plant extracts on duck hepatitis B virus in vitro and in vivo. Antiviral Res. (1992) 18:127–138.
   PubMed Web of Science ®Google Scholar
• MU JZ, WANG YY, QIAO M, GOWANS E, EDWARDS P,THYAGARAJAN SP, GUST I, LOCARNINI S: Effect of Pbyl-lantbus amarus on duck hepatitis B virus replication in vivo. J. Med. ViroL (1990) 32:212–218.
   PubMedGoogle Scholar
• THYAGARAJAN SP, SUBRAMANIAN S, THIRUNALASUN-DARI T, VENKATESWARAN PS, BLUMBERG BS: Effect of Pbyllantbus amarus on chronic carriers of hepatitis B virus. Lancet (1988) 2:764–766.
   PubMed Web of Science ®Google Scholar
• DOSHI JC, VAIDYA AB, ANTARKAR DS, DEOLALIKAR R, ANTANI DH: A two-stage clinical trial of Pbyllantbus amarus in hepatitis B carriers: failure to eradicate the surface antigen. Indian J. Gastroenterol. (1994) 13:7–8.
   PubMedGoogle Scholar
• X1ONG LL: Therapeutic effect of combined therapy of Salvia miltiorrbizae and Polyporus umbetlatus poly-saccharide in the treating chronic hepatitis B. Chin. J. Integrated Trad. Western Med. (1993) 13:533–535.
   Google Scholar
• GUO JT, CHEN HS TANG XS: [Uses of duck hepatitis B virus polymerase and reverse transcriptase in the evalu-ation of anti-hepatitis B virus drugs.] [Chinese]. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih (1992) 12:480–482.
   Google Scholar
• SHINADA M, AZUMA M, KAWAI H, SAZAIU K, YOSHIDA I, YOSHIDA T, SUZUTANI T, SAKUMA T: Enhancement of interferon-gamma production in glycyrrhizin-treated human peripheral lymphocytes in response to conca-navalin A and to surface antigen of hepatitis B virus. Proc. Soc. Exp. Biol. Med. (1986) 181:205–210.
   PubMed Web of Science ®Google Scholar
• TAMURA T: Antiviral effect of glycyrrhizin on duck hepatitis B virus: Effect in duck hepatocyte primary culture. Med. J. Hiroshima Univ. (1991) 39:605–616.
   Google Scholar
• HIYASHI J, KAJIYAMA W, NOGUCHI A, NAKASHIMA K, HLRATA M, HAYASHI S, KASHIWAGI S: Glycyrrhizin with- drawal followed by human lymphoblastoid interferon In the treatment of chronic hepatitis B. Gastmenterol. Jpn. (1991) 26:742–746.
   PubMedGoogle Scholar
• MATSUNAMI H, LYNCH SV, BALDERSON GA, STRONG RW:Use of glycyrrhizin for recurrence of hepatitis B after liver transplantation [letter]. Am. J. Gastroenterol. (1993) 88:152–153.
   PubMed Web of Science ®Google Scholar
• EISENBURG J. [Treatment of chronic hepatitis B. Part 2:Effect of glycyrrhizic add on the course of illness.] [Gennan]. Fortschr. Med. (1992) 110:395–398.
   Google Scholar
• GARCIA GL, SMITH CL, WEISSBERG JI, ET AL.: Adeninearabinoside monophosphate (vidarabine phosphate) In combination with human leukocyte interferon in the treatment of chronic hepatitis B: a randomized, double-blinded, placebo-controlled trial. Ann. Int. Med. (1987) 107:278–285.
   Google Scholar
• YOKOSUKA O, OMATA M, IMAZEKI F, HIROTA K, MORI J, UCHIUMI K, ITO Y, OKUDA K: Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B: a controlled study. Gastroenterology (1985) 89:246–251.
   PubMed Web of Science ®Google Scholar
• FIUME L, BUSI C, CORZANI S, DI STEFANO G, GERVASI GB, MATTIOLI A: Organ distribution of a conjugate of ade-nine arabinoside monophosphate with lactosaminated albumin in the rat [letter]. J. Hepatol. (1994) 20:681–682.
   PubMed Web of Science ®Google Scholar
• FIUME L, BUST C, MATTIOLI A, SPINOSA G: Targeting of antiviral drugs bound to protein carriers. Crit. Rev. Ther. Drug Carrier Syst. (1988) 4:265–284.
   PubMed Web of Science ®Google Scholar
• GALLE PR, THEILMANN L: Inhibition of hepatitis B virus polymerase-activity by various agents. Transient ex-pression of hepatitis B virus DNA in hepatoma cells as novel system for evaluation of antiviral drugs. Arzne-imittelforschung (1990) 40:1380–1382.
   Google Scholar
• MINUK GY, GERMAN GB, BERNSTEIN C, BENARROCH A,GAUTHIER T, SEKLA L: A pilot study of steroid with-drawal followed by oral acyclovir in the treatment of chronic type B hepatitis. Clin. Invest. Med. (1992) 13(0:506–512.
   Google Scholar
• BERK L, SCHALM SW, DE MAN RA, HEYTINK RA, BER-THELOT P, BRECHOT C, BOBOC B, DEGOS, F, MARCELLIN P, BENHAMOU JP ET AL.: Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A Multi-centre randomized controlled triaL J. Hepatol. (1992) 14:305–309.
   Google Scholar
• STASCHKE KA, COLACINO JM, MABRY TE, JONES CD: Thein vitro anti-hepatitis B virus activity of FIAU [1-(2'-de-oxy-2'-i1uoro-1-13-D-arabinofuranosy1-5-iodo)uracR] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res. (1994) 23:45–61.
   PubMed Web of Science ®Google Scholar
• TARTAGLIONE T, HOOTON TM, JONES T, SMILES K, COREY L: Actg 122: Phase II tolerance study of oral FIAU in HIV-infected persons. Int. Conf. AIDS (1991) 7:254. Abstract No. WB2290.
   Google Scholar
• BRAHAMS D: Deaths in US fialuridine trial [news]. Lancet(1994) 343:1494–1495.
   PubMed Web of Science ®Google Scholar
• CHOSSEGROS P, POUTEIL-NOBLE C, SAMUEL D, CAUSSEX, OUZAN D, BIZOLLON T, TOURAINE JL, TREPO C: Gandclovir is an effective antiviral agent for post-trans-plantation chronic HBV infections, maintenance ther-apy may be required in some cases. Gastroenterology (1993) 104:A888.
   Google Scholar
• GISH RG, LAU JYN, BROOKS L, FANG J \VS, STEADY SL, IMPERIAL JC, GARCIA-KENNEDY R, ESQUIVEL CO, KEEFFE EB: Ganciclovir treatment of hepatitis B virus infection In liver transplant recipients. J. Hepatology fin Press].
   Google Scholar
• ANGUS P, RICHARDS M, BOWDEN S, IRETON J, SINCLAIR R, JONES R, LOCARNINI S: Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J. Gastroenterol. and HepatoL (1993) 8:353–357.
   PubMed Web of Science ®Google Scholar
• BOIKE SC, PUB MA, FREED MI, AUDET PR, FAIRLESS A, ILSON BE, ZARIFFA N, JORKASKY DK: Pharmacokinetics of famciclovir in subjects with varying degrees of renal Impairment Ctn. Pharm. Ther. (1994) 55:418–426.
   Web of Science ®Google Scholar
• SHAW T, AMOR P, CIVITICO G, BOYD M, LOCARNINI S: In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents and Chemother. (1994) 38:719–723.
   PubMed Web of Science ®Google Scholar
• BORER KHW, BINGE B, KROGER M, PICHLMAYR R, MANNS MP: Prostaglandin E plus fatnciclovir a new concept for the treatment of severe hepatitis B after liver transplan-tation. Transplantation (1994) 57:1706–1708.
   PubMed Web of Science ®Google Scholar
• VERE HR, SUTTON D, BOYD MR, ET AL.: Selection of an oral prodrug (BRL 42810) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-y1)guan1ne; penciclovir]. Antimicrob. Agents Chemother. (1989) 33:1765–1773.
   Google Scholar
• BERK L, SCHALM SW, HEIJTINK RA: Zidovudine inhibitshepatitis B virus replication. Antiviral Res. (1992) 19(2):111–118.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, BOYER N, COLIN JF, MARTINOT-PEIGNOUX M, LEFORT V, MATHERON S, ERLINGER S, BENHAMOU JP: Recombinant alpha interferon for chronic hepatitis B In anti-HIV positive patients receiving zidovudine. Gut (1993) 34\(Suppl. 2):S106.
   Google Scholar
• GILSON RJ, HAW1UNS AE, KELLY GK, GILL SK, WELLER IV: No effect of zidovudine on hepatitis B virus replication In homosexual men with symptomatic HIV-1 infection. AIDS (1991) 5:217–220.
   PubMed Web of Science ®Google Scholar
• CIVITICO G, WANG YY, LUSCOMBE C, BISHOP N, TACHEDJIAN G, GUST I, LOCARNINI S: Antiviral strategies In chronic hepatitis B virus infection: H. Inhibition of duck hepatitis B virus in vitro using conventional an-tiviral agents and supercoiled-DNA active compounds. J. Med. Virol. (1990) 31:90–97.
   Google Scholar
• SHERICER AN, HIROTA K, OMATA M, OKUDA K: Foscarnet decreases serum and liver duck hepatitis B virus DNA In chronically infected ducks. Gastroenterology (1986) 91:818–824.
   PubMed Web of Science ®Google Scholar
• BAIN VG, DANIELS HN, CHANAS A, ALEXANDER GJ, WIL-LIAMS R: Foscarnet therapy in chronic hepatitis B virus E antigen carriers. J. Med. Virol. (1989) 29:152–155.
   PubMed Web of Science ®Google Scholar
• PRICE JS, FRANCE AJ, MOAVEN 1,D, WELSBY PD: Foscarnet In fukninant hepatitis B [letter]. Lancet (1986) 2:1273.
   PubMedGoogle Scholar
• DOONG SL, TSAI CH, SCHINAZI RF, LIOTTA DC, CHENG YC: Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related ana-logues. Proc. Natl. Acad. Sci. (1991) 88:8495–8499.
   PubMed Web of Science ®Google Scholar
• DLENSTAG JL, PERILLO RP, SCHIFF ER, BARTHOLOMEW M, VICARY C, RUBIN M: Double-blind, randomized, three-month, dose-ranging trial of lamivudine for chronic hepatitis B. Hepatology (1994) 20(4):199A. Abstract No. 412.
   Google Scholar
• CONDREAY LD, JANSEN RW, POWDRILL TFJOHNSON LC, SELLESETH DW, PARE MT, DALUGE SM, PAINTER GR, FURMAN PA, ELLIS MN, ET AL.: Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-142-(hy-droxymethy0-1,3-oxathiolan-5-Acytosine in a novel in vivo modeL Antimicrob. Agents Chemother. (1994) 38:616–619.
   Google Scholar
• FURMAN PA, DAVIS M, LIOTTA DC, PARE M, FRICK LW, NELSON DJ, DORNSIFE RE, WURSTER JA, WILSON LJ, FYTE JA, ET AL.: The anti-hepatitis B virus activities, cytotoxici-ties, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-142-(hydroxymethyl)-1,3oxathiolan-5-ylkytosine. Antimicrob. Agents Chemother. (1992) 36:2686–2692.
   Google Scholar
• FRIED MW, FONG T-L, SWAIN MG, PARK Y, BEAMES MP, BANKS SM, HOOFNAGLE JH, DI BISCEGLIE AM: Therapy of chronic hepatitis B with a 6-month course of ribavirin. J. Hepatol. (1994) 21:145–150.
   PubMed Web of Science ®Google Scholar
• HEIJTINK RA, DE WILDE GA, KRUINING J, BERK L, BALZARINI J, DE CLERCQ E, HOLY A, SCHALM SW: Inhibi-tory effect of 9-(2-phosphonylmethoxyethyl)-atlenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Research (1993) 21:141–153.
   PubMed Web of Science ®Google Scholar
• IKEDA N, KANEKO 5, SHIMODA A, LNAGAKI Y, UNOURA M, OKADA M, YONEICAWA Y, TAKAHASHI K, KOBAYASHI K: Efficacy of oxetanocin-G, a novel nucleoside against the woodchuck hepatitis virus. J. Antimicrob. Chemother. (1994) 33:83–89.
   PubMed Web of Science ®Google Scholar
• HUNG LF, BRUMBAUGH AE, BHATIA G, MARION PL, HUNG PP, NORBECK DW, PLATTNER JJ, ROBINSON WS: Effects of purine nucleoside analogues with a cyclobu-tane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV-1 in cell culture. J. Med. Virol. (1991) 35:180–186.
   PubMed Web of Science ®Google Scholar
• HSIEH SY, TAYLOR J: Delta virus as a vector for the delivery of biologically-active RNAs: possibly a ri-bozyme specific for chronic hepatitis B virus infection. Adv. Exp. Med. Biol. (1992) 312:125–128.
   PubMedGoogle Scholar
• WAKITA T, WANDS JR: Specific inhibition of hepatitis C virus expression by antisense oligonucleotides. J. Biol. Chem. (1994) 269:14205–14210.
   PubMed Web of Science ®Google Scholar
• OFFNSPERGER WB, OFFENSPERGER S, WALTER E, TEUB-NER K, IGLOI G, BLUM HE, GEROK W: In vivo inhibition of duck hepatitis B virus replication and gene expres-sion by phosphorothioate modified antisense oligonu-cleotides. MIRO J (1993) 267:12436–12439.
   Google Scholar
• MA DDF, DOAN TL: Antisense oligonucleotide therapies: are they the "magic bullets"? Ann. Int. Med. (1994) 120:161–163.
   Web of Science ®Google Scholar
• ROLAN PE, PARKER JE, GRAY SJ, WEATHERLEY BC, IN-GRAM J, LEAVENS W, WOOTTON R, POSNER J: The phar-macokinetics, tolerability and pharmacodynamics of tucaresol (589c80; 4[2-formy1-3-hydroxyphe-noxymethylj benzoic acid), a potential anti-sickliag agent, following oral administration to healthy sub-jects. Br. J. Pharmacol. (1993) 35:419–425.
   Web of Science ®Google Scholar
• JANSSEN HL, BERK L,RA, TEN-KATE FJ, SCHALMSW: Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo controlled triaL Hepatology (1993) 17:383–388.
   Google Scholar
• XIONG K-J, ET AL.: Therapeutic effect of combined acy-clovir and interferon treatment on chronic hepatitis B virus infection. Chin. J. Infect. Dis. (1992) 10:84–87.
   Google Scholar
• HAYASHI J, KAJIYAMA W, NOGUCHI A, NAKASHIMA K, HITATAT M, HAYASHI S, KASHIWAGI S: Glycyrrhizin withdrawal followed by human lytuphoblastoid inter-feron in the treatment of chronic hepatitis B. Gastroen-terol. Jpn. (1991) 26:742–746.
   Google Scholar
• CIVITICO G, WANG YY, LUSCOMBE C, BISHOP N, TACHEDJIAN G, GUST I, LOCARNINI S: Antiviral strategies in chronic hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active com-pounds. J. Med. Virol. (1990) 31:90–97.
   PubMed Web of Science ®Google Scholar
• SIDWELL R`OV, HLTFFMAN JH, CALL EW, WARREN RP, RA-DOW LA, MURRAY RJ: Inhibition of murine hepatitis virus infection by the immunomodulator 2,3,5,6,7,8-hexahydro-2-pheny1-8,8-dimethoxy-hnicin7o[1,24pyri dine (PR-879-317A). Antimicrob. Agents Chemother. (1987) 31:1130–1134.
   PubMed Web of Science ®Google Scholar
• UHLMANN E, PEYMAN A: Antisense oligonudeotides: A new therapeutic principle. Chemical Review (1990) 90:544–583.
   Web of Science ®Google Scholar
• ICHIDA F, YOSHIKAWA A, YACHI A, GOTO Y, FURUTA S, HATTORI N, KAKUMU S, KOSAKA Y, TAIUNO T, NA-GASHIMA H, ET AL: Treatment of HBeAg-positive chronic hepatitis with a streptococcal preparation (OK-432). J. Int. Med. Res. (1985) 13:59–67.
   PubMed Web of Science ®Google Scholar
• WADA T, ARIMA T, NAGASHIMA H: Natural killer activity In patients with chronic hepatitis treated with OK432, Interferon, adenine arabinoside and glycyrrhizin. Gas-troenterol.Jpn. (1987) 22:312–321.
   PubMedGoogle Scholar
• NISHIMURA K, ISHIZAKA S, TSUJII T: Predictive indicators for the therapeutic effect of OK-432 in patients with chronic active type B hepatitis. Biotherapy (1992) 4:299–306.
   PubMedGoogle Scholar
• XU X-T: Clinical study of cinobufatolin in treating chronic hepatitis B virus carriers. Chin.J. Integrated Trad. West Med. (1993) 13:473–475.
   Google Scholar
• PETCU DJ, ALDRICH CE, COATES L, TAYLOR JM, MASON WS: Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology (1988) 167:385–392.
   PubMed Web of Science ®Google Scholar
• MORALEDA G, WU TT, JILBERT AR, ALDRICH CE, CON-DREAY LD, LARSEN SH, TANG JC, COLACINO JM, MASON WS: Inhibition of duck hepatitis B virus replication by hypericin. Antiviral Res. (1993) 20:235–247.
   PubMed Web of Science ®Google Scholar
• UN TS, LUO MZ, LIU MC, PAI SB, DUTSCHMAN GE, CHENG YC: Antiviral activity of 2',3'-dideoxy-13-L-5-fluorocytid-ine (f3-L-FddC) and 2',3'-dideox-y-P-L-5-cytidine (0-L-ddC) against hepatitis B virus and human Immunodeficiency virus type 1 in vivo. Biochem. Phar-macol. (1994) 47:171–174.
   PubMed Web of Science ®Google Scholar
• LIN TS, LUO MZ, LIU MC, PAT SB, DIJTSCHMAN GE, CHENG YC: Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrirnidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J. Med. Chem. (1994) 37:798–803.
   PubMed Web of Science ®Google Scholar
• PRICE PM, BANERJEE R, JEFFREY AM, ACS G: The mecha-nism of hepatitis B virus replication by the carbocyclic analog of 2'-deoxyguanosine. Hepatology (1992) 16:8–12.
   PubMed Web of Science ®Google Scholar
• AOKI-SEI S, O'BRIEN MC, FORD H, FUJI H, GILBERT DA, COONEY DA, JOHNS DG, BRODER S. MITSUYA H: In vitro Inhibition of hepatitis B virus replication by 2',3'-dide-oxyguanosine, 2',3'-dideoxyinosine and 3'-oxido-2'3'-dideoxythymidine in 2.2.15(PR) cells. J. Inf Dis. (1991) 164:843–851.
   Google Scholar
• FOUREL I, LI J, HANTZ O, JACQUET C, FOX JJ, TREPO C: Effects of 2'-fluorinated arabinosyl-pyrimidine nucleo-sides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. J. Med. Virol. (1992) 37:122–126.
   PubMed Web of Science ®Google Scholar
• MATTHES E, LANGEN P, VON JANTA-LIPINSKI M, WILL H, SCHRODER HC, MERZ H, WEILER BE, MULLER WE: Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides. Antimicrob. Agents Chemother. (1990) 34:1986–1990.
   PubMed Web of Science ®Google Scholar
• HANTZ O, ALLAUDEEN HS, ()OKA T, DE CLERCQ E, TREPO C: Inhibition of human and woodchuck hepatitis virus DNA polynaerase by the triphosphates of acydovir, 1-(2'-deoxy-2'-f1uoro-P-D-arabino furanosyl)-5-iodocy-tosine and E-5-(2-bromoviny1)-2'-deoxyuridine. Antivi-ral Res. (1984) 4:187–199.
   PubMedGoogle Scholar
• IIZUKA A, WATANABE T, KUBO T, YAMAMOTO M, OGAWA K, OHKUMA T, KAJI A: M13 lbacteriophage DNA Inhibits duck hepatitis B virus during acute infection. Hepatology (1994) 19:1079–1087.
   PubMed Web of Science ®Google Scholar